Sodium-glucose transport protein 2 (SGLT2) inhibitor administration reduces blood glucose levels and is currently the standard intervention for preventing diabetic kidney disease progression and cardiovascular disease in patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.